Key Points
- Alignment Healthcare President Dawn Christine Maroney sold 30,000 shares on June 15 at an average price of $19.55, totaling about $586,500. The sale reduced her ownership by 3.07% and was made under a pre-arranged Rule 10b5-1 trading plan.
- The company reported solid quarterly results, posting EPS of $0.05 versus the expected $0.01 and revenue of $1.24 billion, above estimates. Revenue also rose 33.3% from the same quarter a year earlier.
- Analyst sentiment remains moderately positive, with a consensus rating of “Moderate Buy” and an average price target of $24.30. Recent moves were mixed, including some price-target cuts and upgrades from different firms.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) President Dawn Christine Maroney sold 30,000 shares of the company's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $19.55, for a total value of $586,500.00. Following the completion of the sale, the president owned 947,313 shares of the company's stock, valued at $18,519,969.15. This trade represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dawn Christine Maroney also recently made the following trade(s):
- On Friday, May 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $16.09, for a total value of $482,700.00.
- On Wednesday, April 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $20.87, for a total value of $626,100.00.
- On Wednesday, March 18th, Dawn Christine Maroney sold 36,749 shares of Alignment Healthcare stock. The shares were sold at an average price of $17.84, for a total value of $655,602.16.
Alignment Healthcare Price Performance
ALHC stock opened at $19.78 on Tuesday. The company has a debt-to-equity ratio of 1.56, a current ratio of 1.58 and a quick ratio of 1.58. The business has a 50 day simple moving average of $18.55 and a 200-day simple moving average of $19.42. The firm has a market capitalization of $4.09 billion, a PE ratio of 219.78, a price-to-earnings-growth ratio of 2.67 and a beta of 1.14. Alignment Healthcare, Inc. has a 1 year low of $11.63 and a 1 year high of $23.87.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.04. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.22 billion. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The business's revenue was up 33.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.05) earnings per share. Equities research analysts anticipate that Alignment Healthcare, Inc. will post 0.2 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in shares of Alignment Healthcare by 156.5% during the first quarter. Bank of America Corp DE now owns 3,215,667 shares of the company's stock worth $56,660,000 after buying an additional 1,961,778 shares during the period. Edgestream Partners L.P. purchased a new position in shares of Alignment Healthcare during the first quarter worth $4,852,000. California State Teachers Retirement System boosted its position in shares of Alignment Healthcare by 25.4% during the first quarter. California State Teachers Retirement System now owns 198,200 shares of the company's stock worth $3,492,000 after buying an additional 40,135 shares during the period. Quantinno Capital Management LP boosted its position in shares of Alignment Healthcare by 442.2% during the first quarter. Quantinno Capital Management LP now owns 89,387 shares of the company's stock worth $1,575,000 after buying an additional 72,900 shares during the period. Finally, Orbimed Advisors LLC purchased a new position in shares of Alignment Healthcare during the first quarter worth $13,937,000. 86.19% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research analysts recently weighed in on the company. Barclays lowered their price objective on Alignment Healthcare from $19.00 to $16.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 26th. UBS Group increased their price objective on Alignment Healthcare from $21.00 to $22.00 and gave the stock a "neutral" rating in a research report on Friday, May 1st. Weiss Ratings upgraded Alignment Healthcare from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Thursday, May 7th. Wall Street Zen upgraded Alignment Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. Finally, Raymond James Financial set a $22.00 price objective on Alignment Healthcare in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $24.30.
Get Our Latest Stock Analysis on Alignment Healthcare
Alignment Healthcare Company Profile
(
Get Free Report)
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
